Safety and tolerability of spesolimab in patients with ulcerative colitis

Review Gastroenterology & Hepatology

A systematic review and meta-analysis of outcomes after elective surgery for ulcerative colitis

D. M. Baker et al.

Summary: The study aims to summarize the outcomes after elective surgery for ulcerative colitis (UC). Results showed variable definitions and outcomes, providing practical information for shared decision making in clinical practice.

COLORECTAL DISEASE (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

Catherine Le Berre et al.

Summary: The SPIRIT consensus group has agreed that the ultimate therapeutic goal in both CD and UC is to prevent disease impact on patients' lives, including health-related quality of life, disability, and fecal incontinence, as well as prevent complications in the short and long term, such as bowel damage, surgeries, disease extension, extraintestinal manifestations, and dysplasia or cancer. These recommendations will need to be validated in clinical studies before being implemented in disease-modification trials.

GASTROENTEROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Trial of Spesolimab for Generalized Pustular Psoriasis

H. Bachelez et al.

Summary: In a phase 2 randomized trial, spesolimab, an interleukin-36 receptor inhibitor, showed a higher rate of lesion clearance in GPP patients compared to placebo, but was associated with risks of infections and systemic drug reactions. Further longer and larger trials are needed to assess the efficacy and safety of spesolimab in patients with pustular psoriasis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Dermatology

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

Ulrich Mrowietz et al.

Summary: Palmoplantar pustulosis (PPP) is a chronic, inflammatory skin disease with high disease burden, and there is a high unmet clinical need for effective treatment options. This study evaluated the safety and efficacy of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients with PPP. Although the primary efficacy endpoint was not met, spesolimab showed a potential treatment effect with a higher rate of achieving PPP ASI50 compared to placebo, and was well tolerated with no significant safety concerns.

DERMATOLOGY AND THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Ulcerative colitis: an update

Jonathan P. Segal et al.

Summary: Ulcerative colitis is a relapsing and remitting inflammatory bowel disease characterized by mucosal inflammation with a rising incidence and prevalence. Management focuses on rapid symptom relief, mucosal healing, and improved quality of life, with 5-aminosalicylate acid medications as first-line treatment escalating to immunosuppressive and biologics as needed. Despite best medical therapy, some patients may require surgery, and future treatments may offer more personalized options.

CLINICAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Ulcerative colitis: understanding the impact of ulcerative colitis on everyday life and exploring the unmet needs of patients

Philip O'Hagan et al.

Summary: This market research identified early referral to secondary care and reducing waiting times for investigation as key factors in improving the quality of life for patients with ulcerative colitis (UC). Patients expressed a desire for specialists to discuss their condition with them immediately following diagnosis and involve them in the development of their individual treatment plans.

CURRENT MEDICAL RESEARCH AND OPINION (2021)

Add to Collection

Review Medicine, General & Internal

Twenty-five years of biologicals in IBD: What′s all the hype about?

Klaus R. Herrlinger et al.

Summary: Biologicals have shown significant efficacy in treating diseases like Crohn's, but are only effective in a minority of patients. In real-life studies, outcomes are slightly better and mucosal healing is associated with improved prognosis. However, further research is needed to confirm the effectiveness of the "treat to target" strategy.

JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Clinical Course of Ulcerative Colitis Associated with an Age at Diagnosis: A Recent Japanese Database Survey

Yosuke Shimodaira et al.

Summary: The study investigated the incidence and clinical characteristics of ulcerative colitis patients in Japan, with a focus on late-onset patients. It was found that most patients received 5-aminosalic acid treatment within 12 months of diagnosis, while surgical treatment was more common in elderly patients.

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Editorial Material Biotechnology & Applied Microbiology